Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) – Pipeline Review, H1 2017’, provides in depth analysis on Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Hematological Disorders, Genetic Disorders, Immunology, Oncology and Toxicology under development targeting Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)

– The report reviews Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)targeted therapeutics and enlists all their major and minor projects

– The report assesses Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Daiichi Sankyo Company Ltd

Noxxon Pharma AG

Pieris Pharmaceuticals Inc

Protagonist Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Overview

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Companies Involved in Therapeutics Development

Daiichi Sankyo Company Ltd

Noxxon Pharma AG

Pieris Pharmaceuticals Inc

Protagonist Therapeutics Inc

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Drug Profiles

lexaptepid pegol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-009 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRS-080 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PTG-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Replace Hepcidin for Iron Overload Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Hepcidin for Acute Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Dormant Products

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Discontinued Products

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Product Development Milestones

Featured News & Press Releases

Jul 28, 2016: Protagonist Therapeutics Receives SBIR Funding for the Development of Injectable Hepcidin Mimetics for Treatment of Iron Overload Disorders

May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases

Dec 07, 2015: Pieris Pharmaceuticals Presents Clinical Data for its Hepcidin Antagonist Program, PRS-080, at the 2015 American Society Of Hematology Annual Meeting

Nov 05, 2015: Pieris Pharmaceuticals Announces Presentation Of Clinical Data For Its Hepcidin Antagonist Program, Prs-080, At The 2015 American Society Of Hematology Annual Meeting

Jun 10, 2015: Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia

Dec 11, 2014: Pieris Initiates Phase I Clinical Trial for Anticalin to Treat Anemia

Jul 31, 2014: NOXXON Pharma Initiates Phase IIa Study Of Anti-Hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94) In Dialysis Patients With EPO-hypo-responsive Anemia

Apr 08, 2014: Anti-Hepcidin Spiegelmer Lexaptepid Pegol Increases Hemoglobin in Subset of Anemic Patients in Pilot Phase IIa Study

Dec 06, 2012: Noxxon Pharma To Present Phase I Data Of NOX-H94 At ASH Annual Meeting 2012

Dec 04, 2012: Noxxon Pharma Initiates Phase IIa Clinical Trial Of Anti-hepcidin Spiegelmer NOX-H94

Dec 13, 2011: Pieris Presents Preclinical Data For PRS-080 Hepcidin Antagonist Anticalin Program At ASH Annual Meeting

Sep 06, 2011: NOXXON Initiates Phase I Clinical Trial Of NOX-H94 For Anemia Of Chronic Disease

May 23, 2011: Pieris Announces Preclinical In Vitro And In Vivo Data For Anticalin PRS-080 Hepcidin Antagonist Drug Program

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indication, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Pipeline by Noxxon Pharma AG, H1 2017

Pipeline by Pieris Pharmaceuticals Inc, H1 2017

Pipeline by Protagonist Therapeutics Inc, H1 2017

Dormant Projects, H1 2017

Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports